Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Therapeutic Advances in Medical OncologyOpen Access

Efficacy and safety of a novel treatment scheme of RC48-ADC plus PD-1 inhibitors in metastatic urothelial carcinoma: a multicenter real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJun LinYWYaoan WenJHJie Huang

Discussion

Loading...

Member takes

Overview

Multicenter study finds RC48 plus PD-1 inhibitors improve progression-free survival as first-line therapy for metastatic urothelial carcinoma.

Key Points

  • Complete response achieved in 19% of patients with metastatic urothelial carcinoma.
  • Median progression-free survival reached 10.5 months for the treatment with RC48 and PD-1 inhibitors.
  • Multicenter retrospective cohort study assessing real-world efficacy and safety of the combination treatment.
  • Results suggest potential benefits and manageable safety for first-line therapy in advanced cancer patients.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/6930dc5fea1aef094cca1ccbhttps://doi.org/10.1177/17588359251395928
View Full Paper
Ask AI
Bookmark
Share